Investigation of the safety of Ursodeoxycholic acid (Cholicray)

Phase 2

Recruiting

• Conditions: Condition 1: Primary biliary cirrhosis. Condition 2: Fatty (change of) liver, not elsewhere classified(Nonalcoholic fatty liver disease [NAFLD]). Condition 3: Calculus of bile duct. Condition 4: cholangitis.; Primary biliary cirrhosis; Fatty (change of) liver, not elsewhere classified; Calculus of bile duct with cholangitis; Cholangitis; K74.3; K76.0; K80.3; K83.0

• Registration Number: IRCT20210914052480N3
• Lead Sponsor: Reyhaneh Pharmaceutical Company

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 August 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

above 18 years old
Consent to participate in the study
Presence of liver or biliary disorders such as fatty liver, cholangitis, Primary biliary cirrhosis, Calculus of bile duct.

Exclusion Criteria

pregnancy

Study & Design

• Study Type: interventional
• Study Design: Not specified